T HE antiinflammatory properties of nonsteroidal antiinflammatory drug (NSAID) therapy appear to result from their common ability to inhibit cyclooxygenase, a major enzyme in the biosynthesis of prostaglandins, which in turn act as local regulators of cell function (1, 2) . The effects of various prostaglandins are quite diverse and incjude vasodilatation and vasoconstriction, platelet aggregation and disaggregation, and mediation of the inflammatory response. Regulation of these often contradictory physiologic effects is accomplished through the differential synthesis of distinct types of prostaglandins. A variety of adverse drug effects have been attributed to the inhibition of prostaglandin biosynthesis in the setting of NSAID therapy. These include an assortment of renal syndrome (3), exacerbation of congestive heart failure (4), and antagonism of antihypertensive control.
There is good evidence to suggest an important role for prostaglandins in the modulation of two major determinants of blood pressure: the vasoconstriction of arteriolar smooth muscle and the control of extracellular fluid volume. Prostaglandins counteract the response to vasoconstrictor hormones through their vasodilatory actions. In addition, prostaglandins can influence sodium balance as a result of their natriuretic effects (5, 6) . The finding of low basal levels of prostaglandins in hypertensive patients suggests that a deficiency in vasodilator prostaglandins may contribute to essential hypertension (7, 8) .
The effect of NSAIDs on blood pressure control may have the most important clinical implications for treated hypertensive patients. Various studies have suggested that NSAIDs can blunt or abolish the antihypertensive effects of many hypotensive agents including diuretics, betaadrenergic blockers, vasodilators, and centrally acting alpha-agonists (9) .
The clinical implications of the interaction between NSAID therapy and hypertension may be of greatest importance for the elderly. Among those 65 years of age and older, it has been estimated that 10 to 15% take prescribed NSAID (10) . Approximately 33% of Whites and 40% of Blacks over age 65 have either isolated systolic hypertension or combined systolic-diastolic hypertension (11) . Since osteoarthritis and hypertension are so prevalent in the geriatric population, the coadministration of chronic NSAID therapy and antihypertensive drugs is extremely common. In addition, there is some evidence to suggest that patients v/ith lowrenin essential hypertension are more susceptible to the antagonistic effects of NSAIDs on antihypertensive therapy (9, 12) . This may be of particular relevance to the geriatric
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To examine the effect of NSAID therapy on the control of hypertension in elderly persons, we conducted a randomized, double-blind, two-period crossover trial of ibuprofen vs placebo treatment in older hypertensive patients controlled with hydrochlorothiazide.
METHODS
Study subjects. -Subjects enrolled in the study were older than 60 years of age with a documented history of essential hypertension (diastolic > 90 mmHg and/or systolic > 150 mmHg) and using hydrochlorothiazide as an antihypertensive. The study was approved by the Harvard Medical School Committee on Human Studies and by the Research and Development Committee and the Human Subjects Subcommittee of the Department of Veterans Affairs Medical Center (Brockton/West Roxbury, MA). All subjects provided written informed consent before their participation in the study. Subjects were screened by interview, physical examination, and laboratory studies (hemoglobin, hematocrit, serum electrolytes, serum urea nitrogen, and serum creatinine) prior to entry into the study. Those with a history of unstable hypertension, secondary hypertension, serum creatinine > 2.5 mg/dL, poorly compensated congestive heart failure, hepatic insufficiency, NSAID allergy or intolerance, gastrointestinal hemorrhage, or current anticoagulant or aspirin use (>325 mg per day) were excluded from participation.
Procedures. -This investigation employed a randomized, double-blind, two-period crossover, placebocontrolled design. Subjects were maintained on their usual hydrochlorothiazide regimen throughout the study. They were asked not to alter their diet and life-style habits in any way during the course of the study, including salt intake, coffee consumption, or the use of alcohol or tobacco. The subjects were also requested not to alter the dosage or timing of their usual medications during the course of the study. Subjects were requested to avoid use of prescription or overthe-counter NSAIDs during the study. Acetaminophen was made available to participants to be used as needed for pain, in dosages up to one gram q.i.d.
The study protocol began with a 2-week, single-blind, run-in phase during which all subjects took placebo tablets t.i.d. that were identical in appearance to ibuprofen 600 mg tablets. At the end of this 2-week period, subjects were randomly assigned (according to a computer-generated list of random numbers) to receive either ibuprofen 600 mg t.i.d. or placebo tablets in a double-blind fashion. At the end of a 4-week treatment period, subjects underwent a 2-week single-blind, placebo washout period; then they crossed over to the alternative treatment (either ibuprofen or placebo) for a final 4-week treatment period.
During the study, subjects returned to the research clinic weekly. Their blood pressure was taken in the same arm throughout the duration of the study by a research assistant blinded to treatment status, using a Critikon Dynamap® oscillometric blood pressure measuring device. Measurements were obtained at a consistent time relative to the morning dose of study medication (ibuprofen or placebo) and hydrochlorothiazide. Blood pressure, heart rate, and mean arterial pressure were determined in the supine position after 5 minutes, and then in the standing position after one minute. All measurements were obtained in a consistent manner. Blood pressures in the standing position were obtained with the arm extended at the subject's side. Measurements were taken in each position three times, with each measurement separated by one minute. For the purpose of this study, the mean of the second two measurements in each position was utilized in all analyses. Body weight as measured without shoes or heavy clothing was recorded at each visit. Serum electrolytes (sodium, potassium, chloride), serum urea nitrogen, serum creatinine, and hematocrit were determined at 2-week intervals throughout the study period.
At each weekly visit, subjects received a one-week supply of ibuprofen or placebo tablets. Pill counts of the previous week's medication use (study medication and hydrochlorothiazide) and a careful drug history regarding all medications used by the subject were performed. Subjects found to deviate from the prescribed drug regimen (study medication and/or hydrochlorothiazide) by more than 20% during the study were discontinued.
Statistical analysis. -We compared measurements at corresponding times after initiation of ibuprofen or placebo using a two-tailed Student f-test for paired data. The /-tests were corrected for multiple comparisons by the method of Bonferroni (15) . For instances in which a blood pressure measurement was not obtained, the corresponding measurement for that subject during the alternative treatment period was also not included in the respective analysis.
Repeated measures analysis of variance (ANOVA) was used to assess the overall effect of treatment (ibuprofen or placebo) on systolic, diastolic, and mean arterial blood pressures. These analyses employed data for all values of blood pressure measurements for each of the two 4-week treatment periods (ibuprofen and placebo). Each 4-week treatment period included five observation points at weekly intervals including the baseline time point. Baseline measurements for each respective treatment period were always obtained while the subject was receiving placebo treatment. For each subject completing the study protocol, there were up to four measurements on ibuprofen and six measurements on placebo for each blood pressure parameter. Models included factors for treatment effect, as well as terms for group assignment (based on treatment sequence) and time.
Repeated measures ANOVA was also used to compare serum sodium, serum potassium, serum urea nitrogen, serum creatinine, hemoglobin, hematocrit, and weights in the two treatment periods. These analyses employed data for all values of these parameters for each of the two 4-week treatment periods (ibuprofen and placebo); three measurements were obtained: baseline, 2 weeks, and 4 weeks. For each subject completing the study protocol, there were up to two measurements on ibuprofen and three measurements on placebo for each parameter.
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All results are presented as the mean ± standard deviation except where specifically indicated (see Figures). For the purpose of this study, p-values < .05 were considered statistically significant.
RESULTS
Twenty-five subjects were randomized following the initial 2-week, single-blind, placebo run-in phase. Three subjects were withdrawn subsequent to randomization: one because of noncompliance with the study protocol and inadequate consumption of study medication based on pill counts; one because of the occurrence of osteoarthritis pain that was not adequately controlled with acetaminophen; and one after an increase in serum urea nitrogen and serum creatinine from 24 mg/dL and 1.1 mg/dL to 53 mg/dL and 1.8 mg/dL, respectively, over a 2-week period of treatment (determined to be ibuprofen after unblinding).
Twenty-two subjects with an average age of 73 (±6.7) years completed the study protocol; a summary of baseline characteristics is presented in Table 1 . All 22 subjects were White. Among the 22 subjects, there were two cigarette smokers. Fourteen subjects reported use of alcohol; of these, nine reported consumption of less than one drink per day and five reported consumption of one or more drinks per day. Twenty subjects reported use of caffeinated coffee; of these, three subjects reported consumption of less than one cup per day and 17 indicated drinking one or more cups daily. In addition to hypertension, subjects had an average of 1.7 chronic medical conditions (range, 0 to 4); 68% (n = 15) had degenerative joint disease. In addition to hydrochlorothiazide and the study medication (ibuprofen or placebo), subjects were taking an average of 0.9 other medications on a regular basis (range, 0 to 3). A review of these medications indicated that two subjects were receiving treatment with medications during the study with the potential for hypotensive effects: isosorbide dinitrate (n = 1) and metoprolol (n = 1) for coronary artery disease. These subjects did not alter their use, dosage, or timing of administration of these agents throughout the study. Careful medication histories performed at weekly intervals throughout the course of the study indicated that there was no use of nonstudy medications by subjects with a potential for hypertensive effects (e.g., decongestants containing phenylpropanolamine) (16, 17) . One subject did not attend one scheduled weekly visit. Standing blood pressure measurements were not obtained for one additional subject at one visit. For the group of 22 study subjects who completed the study protocol, measurements of blood pressure were complete for over 99% of 220 scheduled visits encompassing the two 4-week treatment periods (ibuprofen and placebo). Figure 1 summarizes supine systolic and diastolic blood pressure measurements at the weekly observation points for the ibuprofen and placebo treatment periods. The comparisons at the end of Week 3 employed data for only 21 subjects. All other analyses included data for all 22 subjects. Differences in supine systolic blood pressure between ibuprofen and placebo treatment reached statistical significance after Bonferroni correction only at Week 2 ( < .05). There were no other statistically significant differences in supine systolic or diastolic blood pressure measurements at any of the other observation points. Figure 2 summarizes standing systolic and diastolic blood pressure measurements at the weekly observation points for the ibuprofen and placebo treatment periods. The comparisons at the end of Week 3 employed data for only 20 subjects. All other comparisons included data for all 22 subjects. Differences in standing systolic blood pressure between ibuprofen and placebo treatment reached statistical Figure 1 . Supine systolic and diastolic blood pressure measurements at the weekly observation points for the ibuprofen and placebo treatment periods. Brackets indicate standard errors of the mean. At baseline, both groups were receiving placebo. The comparisons at the end of Week 3 employed data for only 21 subjects. All other analyses included data for all 22 subjects. Differences in supine systolic blood pressure between ibuprofen and placebo treatment reached statistical significance after Bonferroni correction only at Week 2 (p < .05). Figure 2 . Standing systolic and diastolic blood pressure measurements at the weekly observation points for the ibuprofen and placebo treatment periods. Brackets indicate standard errors of the mean. At baseline, both groups were receiving placebo. The comparisons at the end of Week 3 employed data for only 20 subjects. All other comparisons included data for all 22 subjects. Differences in standing systolic blood pressure between ibuprofen and placebo treatment reached statistical significance after Bonferroni correction only at the end of Week 4 (p < .05).
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significance after Bonferroni correction only at the end of Week 4 (/? < .05). There were no other statistically significant differences in standing systolic or diastolic blood pressure measurements at any of the other observation points.
Assessments of the effect of treatment status on blood pressure measurements using analysis of variance accounting for repeated measures are summarized in Table 2 . Statistically significant differences between ibuprofen and placebo treatment were observed for supine systolic blood pressure (143.8 ± 21.0mmHgvs 139.6 ± 15.9 mmHg,/? = .004), supine mean arterial pressure (102.1 ± 13.8 mmHgvs99.5 ± 10.1 mmHg, p = .01), standing systolic pressure (148.1 ± 19.9 mmHg vs 143.4 ± 17.9 mmHg,/? = .002), and standing mean arterial pressure (106.1 ± 15.4 mmHgvs 102.9 ± 12.4 mmHg,/? = .01).
We also evaluated the effect of the treatment sequence to which subjects were randomized to examine whether there was a treatment-by-period interaction (18) . In this analysis, we found some evidence for interaction, with a more pronounced effect on blood pressure for those subjects who received ibuprofen during the second treatment period. For example, in this subgroup (n = 11), the mean difference in standing systolic blood pressure on ibuprofen vs placebo was 9.5 ± 3.5 mmHg (/? = .02). Subjects who had been randomized to this sequence of treatments had higher blood pressures at baseline.relative to those randomized to the alternative sequence (mean ± SD standing systolic pressure 153.6 ± 14.4 mmHgvs 141.0 ± 22.3 mmHg). Randomization did not balance this potentially important covariate in the study. Considering only those subjects who received ibuprofen during the first treatment period, differences in blood pressure on ibuprofen and placebo treatment were smaller and not significant (mean difference in standing systolic blood pressure on ibuprofen vs placebo was 2.4 ± 1.8).
In view of the substantial difference in baseline blood pressures for subjects randomized to the two different sequences of treatment, we examined the characteristics of tMean (±5D) values for measurements on 22 patients at up to 6 time points on placebo.
tANOVA. §Mean arterial pressure. tANOVA.
each group for use of cigarettes, ethanol, coffee, medications with the potential for hypotensive effects besides hydrochlorothiazide, and the hydrochlorothiazide dosage. The subjects who received ibuprofen during the second treatment period and who had higher blood pressures at baseline had similar characteristics to subjects randomized to the alternative treatment sequence in terms of use of ethanol, caffeinated coffee, and hydrochlorothiazide dosage. However, the two smokers and the two subjects using medications with the potential for hypotensive effects (isorbide dinitrate and metoprolol) were included in the group who received ibuprofen during the first treatment period. We do not believe that these differences in patient characteristics would account for the observed differences between the two groups in baseline blood pressure or the effect of ibuprofen on blood pressure.
As summarized in Table 3 , serum urea nitrogen and serum creatinine were significantly increased on ibuprofen relative to placebo treatment (/? = .001). Hemoglobin and hematocrit were significantly reduced and body weight was increased (/? = .001). For the overall population, these differences were of questionable clinical significance. However, one subject taking ibuprofen did experience an asymptomatic 6-point reduction in hematocrit that returned to baseline subsequent to completion of the protocol. No source for this was determined. In addition, one subject who did not complete the study protocol developed renal insufficiency on ibuprofen as detailed above.
DISCUSSION
In the present study, the administration of ibuprofen (1800 mg per day), on average, produced small increases in systolic and mean arterial blood pressure relative to treatment with placebo in older subjects with hypertension treated with hydrochlorothiazide. While significant differences between treatment with ibuprofen and placebo were not demonstrated at most of the individual observation points due to the limited power of the study to detect significant differences at any given week, analyses that included all available data from all observation points did reveal significant differences. The observed increases in systolic pressure out of proportion to changes in diastolic pressure are of special interest in regard to the geriatric population. In older patients with systolic hypertension, an increase in pulse pressure is a principal hemodynamic hallmark relating to a reduction in arterial compliance (19) . NSAID therapy might potentiate this situation through the inhibition of prostaglandin biosynthesis.
To the best of our knowledge, this is the first study to examine the effects of NSAID therapy on blood pressure control in a trial comprised solely of older subjects. Previously published randomized, placebo-controlled trials of the effects of ibuprofen administered to patients with controlled hypertension have produced varying results. Radack and Deck (20) performed a 3-week, parallel trial of 41 patients (mean age = 52 years) with essential hypertension controlled with at least two antihypertensive agents who were randomized to ibuprofen 1200 mg per day, acetaminophen, or placebo. Blood pressure in the ibuprofen group was significantly increased compared with the placebo and acetaminophen groups. By contrast, in a crossover trial, Wright et al. (21) reported no significant change in blood pressure in 12 patients (mean age = 49 years) with essential hypertension controlled with hydrochlorothiazide in whom the effect of one week of treatment with high-dose ibuprofen (3200 mg per day) was compared with placebo.
In two separate crossover trials, Davies et al. (22) studied the effect of ibuprofen 1600 mg per day on blood pressure in one group of patients with hypertension controlled with bendrofluazide (n = 7) and a second group treated with propranolol (n -8). No significant increase in blood pressure was observed in either group with 2 weeks of ibuprofen treatment compared with placebo. Although differences between ibuprofen and placebo treatment were not significant in the studies of Wright and Davies, small increases in mean blood pressure were observed with ibuprofen treatment (2-4 mmHg). Sample size limitations may explain the absence of a statistically significant effect in these studies.
Two meta-analyses have recently been published examining the effect of NSAIDs on blood pressure. Johnson et al. (23) presented the pooled results of 50 randomized, placebocontrolled trials which indicated that NSAIDs, as a class, elevated supine mean arterial blood pressure by 5.0 mmHg. Effects were greatest in medication-controlled hypertensive patients. Among the NSAIDs, piroxicam, indomethacin, and ibuprofen produced the most marked increases in blood pressure. Pope and colleagues (24) examined the findings of 54 studies with 123 NSAID treatment arms in order to rank the individual NSAIDs by magnitude of change in mean arterial pressure. They too found that NSAIDs increased blood pressure solely in patients with existing hypertension. After adjusting for dietary salt intake, increases in mean arterial pressure were greatest for naproxen and indomethacin (3.7 and 3.6 mmHg, respectively). In contrast to the findings of Johnson et al., no increase in mean arterial pressure was noted with ibuprofen. Of note, the mean age of the 1,324 subjects participating in the 54 studies examined by Pope et al. was only 46 years.
A number of epidemiologic studies have examined the impact of NSAID therapy on blood pressure control. Chrischilles and Wallace (25) identified NSAID users among participants in the IOWA 65-I-Rural Health Study and matched them to nonusers according to body mass index and other potentially confounding variables such as age, gender, and use of antihypertensive drugs. They found that among subjects taking antihypertensives, NSAID users were significantly more likely to have systolic blood pressure above 140 mmHg. Another recently reported community-based, cross-sectional study of 2,805 persons over 60 years of age found that after adjusting for body mass index, as well as age, sex, prevalent coronary artery disease, smoking, and alcohol use, NSAID use remained significantly associated with the presence of hypertension or the use of antihypertensive medications (26) . A case-control study of New Jersey Medicaid enrollees aged 65 and older indicated a significantly increased risk for the initiation of antihypertensive therapy in older persons taking NSAIDs, with risk increasing with increasing NSAID dose. These findings suggest that the small to modest increases in blood pressure that have been attributed to NSAID therapy in clinical studies may have clinical relevance (7).
In conclusion, our findings suggest that elderly patients with controlled hypertension who use ibuprofen may experience small but clinically relevant increases in blood pressure. The use of both prescription and over-the-counter NSAIDs should be carefully assessed when elevations in blood pressure are detected in treated hypertensive patients before consideration is given to intensifying the antihypertensive regimen.
